Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 477.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
IVO On Other Exchanges
As of 11:35 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

imperial innovations group p (IVO) Snapshot

481.00 GBp
Previous Close
477.00 GBp
Day High
481.00 GBp
Day Low
477.00 GBp
52 Week High
12/23/14 - 520.00 GBp
52 Week Low
06/3/14 - 400.00 GBp
Market Cap
Average Volume 10 Days
-0.02 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

imperial innovations group p (IVO) Related Businessweek News

No Related Businessweek News Found

imperial innovations group p (IVO) Details

Imperial Innovations Group plc is a venture capital and private equity firm specializing in all stages of development including incubation, seed, early stage, growth capital, development funding, and later stage investments. The firm typically invests in all sectors. It focuses on technology, all-things-saas (software-as-a-service), analytics, security, bioengineering, therapeutics, software, hardware, healthcare, medical devices, and diagnostics, energy, engineering, materials, clean tech, digital, environment, and bioscience companies founded by or based on technology and intellectual property from the University of Oxford, the University of Cambridge, Imperial College, and University College, London. It primarily invests in companies based in the United Kingdom. The firm typically invests between £0.02 million ($0.03 million) and £1 million ($1.71 million). It also invests between £1 million ($1.71 million) and £5 million ($8.55 million) and further between £5 million ($8.55 million) and above £25 million ($42.76 million) for stake building purposes. The firm prefers to lead or co-lead its investments. It also makes subsequent funding technology rounds working in partnership with founders, management, and co-investors. The firm seeks to take a board seat on its portfolio companies. It also provides technology transfer services and targets companies based on the intellectual property from Imperial College. Imperial Innovations Group plc was founded in 1986 and is based in London, the United Kingdom with an additional office in Cambridge, United Kingdom.

64 Employees
Last Reported Date: 11/12/14
Founded in 1986

imperial innovations group p (IVO) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 403.0K GBP
Managing Director of Technology Transfer Offi...
Total Annual Compensation: 135.0K GBP
Chief Investment Officer, Director, and Membe...
Total Annual Compensation: 352.0K GBP
Compensation as of Fiscal Year 2014.

imperial innovations group p (IVO) Key Developments

Imperial Innovations Group plc Names Roberto Solari as Independent Non-Executive Chairman

Imperial Innovations Group plc announced that Dr. Roberto Solari, a recently appointed Venture Partner at the company has joined the board of directors as its independent non-executive chairman. Previously Vice President in GSK's UK-based Respiratory Therapy Area he is currently senior research fellow in the National Heart and Lung Institute, Imperial College London, focusing on respiratory infections.

Imperial Innovations Group plc Presents at Bio-Trinity, May-13-2015 11:10 AM

Imperial Innovations Group plc Presents at Bio-Trinity, May-13-2015 11:10 AM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Nigel Aaron Pitchford, Chief Investment Officer, Director and Member of Investment Committee.

Imperial Innovations Group plc Announces Consolidated Unaudited Earnings Results for the Six Months Ended January 31, 2015

Imperial Innovations Group plc announced consolidated unaudited earnings results for the six months ended January 31, 2015. For the period, the company reported revenue of £2,840,000 against £1,584,000 a year ago, better than the prior half year as a result of a good license and royalty income stream. Operating loss was £7,516,000 against operating income of £24,316,000 a year ago. Loss before taxation was £7,035,000 against profit before tax of £24,353,000 a year ago. Loss for the financial period and total comprehensive income was £7,035,000 against profit of £24,353,000 a year ago. The loss has primarily arisen due to a fall in the value of the quoted portfolio, however the unquoted portfolio has shown a net gain. Diluted loss per share was 5.2 pence against earnings per diluted share of 24.6 pence a year ago. Net cash used in operating activities was £5,168,000 against £3,124,000 a year ago. Purchase of property, plant and equipment was £13,000 against £22,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IVO:LN 477.00 GBp 0.00

IVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Health Discovery Corp $0.02 USD +0.0025
MDxHealth €4.94 EUR -0.032
Miraculins Inc C$0.09 CAD 0.00
Myriad Genetics Inc $32.89 USD -0.07
Vermillion Inc $2.16 USD +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation IVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 133.4x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 134.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPERIAL INNOVATIONS GROUP P, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at